Authors


George P. Sillup, PhD

Latest:

Pressed Into Action: Measuring Pharma’s Reputation Reversal

Study analyzes mainstream media coverage of the industry before and after the COVID-19 lockdown.




Robert A. Musacchio

Latest:

More Than a Game of Keep Away

Industry self-policing may be the only way to stop state Legislators who want to ban sales Reps, and even whole companies, from using Prescribing information.


Patrick Angelastro

Latest:

Special Report: Platform Drugs—Marketing Your Opportunities

Tracking business by indication is critical for evaluating market performance and making accurate resource allocations



Ian Wilcox

Latest:

The Diversity Dearth in Pharma

Why the industry needs more women in senior management roles-and the three strategies to get there.



Peter Pitts

Latest:

If It Walks Like a Duck

Dietary supplements function like drugs and are marketed like drugs. They should be regulated like ducks.


David N. Stievater

Latest:

Sewing Up New Sales

More than high-call frequency will be necessary to succeed in an increasingly competitive sales environment.


Mark Senak

Latest:

Closing the Digital Gap: FDA’s Oversight of Social Media

The parameters governing pharma promotional speech in digital and social media have struggled to keep pace with the rapidly evolving healthcare communications landscape. How can FDA play catch-up in advancing an agenda more reflective of industry and patient needs?



Wendy Huang

Latest:

Medicare Part D: D for Doomed?

As seniors become frustrated and Part D enrollment lags, drug benefit plans cannot grow fast enough to manage risk. Some leave the market, and others cut benefits.


Jason Pesile

Latest:

Medicare Part D: D for Doomed?

As seniors become frustrated and Part D enrollment lags, drug benefit plans cannot grow fast enough to manage risk. Some leave the market, and others cut benefits.



Eleanor O'Rangers

Latest:

Marketing to Professionals: Savvy Strategists

These "guns for hire" bring the science and marketing savvy that clients need, often with in-depth category experience, but without the commitment and cost associated with hiring a full-time employee.


Andrew Chadwick-Jones

Latest:

Vaccines: Market on the Rebound

Mergers have cut the field of companies with real marketing and manufacturing muscle from 25 to five. The 2004 vaccine market will double by 2009.



Kenneth A. Getz

Latest:

Anticipating Digital Transformation of the Drug Development Workforce

The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.



Michele Goldberg

Latest:

PE's Annual Sales and Marketing Employment Survey: The Big Squeeze

In spite of pharmaceutical employers' best intentions to the contrary, sales rep compensation is being squeezed in a vise that is gradually narrowing the gaps between what top, average, and bottom performers are earning. According to the Hay Group's Pharmaceutical Sales Force Effectiveness Study, co-sponsored by Pharmaceutical Executive, reps in the 90th percentile are earning just 40 percent more than the average performer. This is not to suggest that reps aren't being paid handsomely (they are), but that the pay-for-performance model is showing signs of weakness.


Michael Fronstin

Latest:

A Fresh Look at Co-morbidity

As americans age, they are likely to suffer from more than one chronic condition at a time. So as the country's population grays, the rate at which patients presenting co-morbid indications will increase, as will the absolute number of patients whose treatment must be adjusted for more than one disease. These are not surprising facts, but they deserve careful consideration by pharma manufacturers and marketers.


Otavio Freire

Latest:

Marketing to Professionals: Key Opinion Control

Marketing effectively to physicians in today's pharmaceutical industry is more important than ever. No longer can companies rely solely on DTC and sales force efforts to increase drug and therapeutics revenue.


Ed Yavuz

Latest:

What Does It Take to be a Global Leader in Training

Our goal is competency-based training that has a solid business need, sound instructional design based on adult-learning principles, and metrics that can capture, evaluate, and track what we do. We want a blended-learning approach that can be delivered over the Web, on CD-ROM, or on paper.


Amy Katzenberg

Latest:

Unleash the Tablets

Some reps take to tablet PCs like ducks to water, while others wait for them to become the gold standard. Good training can put everyone on the same page.


Anthony Manson

Latest:

Unleash the Tablets

Some reps take to tablet PCs like ducks to water, while others wait for them to become the gold standard. Good training can put everyone on the same page.




Patrick Clinton

Latest:

Pharm Exec 50: Growth from the Bottom Up

More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.


Rayna Herman

Latest:

Nobody Does it Better

If you work for a company that isn't interested in increasing sales across your portfolio, don't read this article. Otherwise, you'll learn that your district managers (DM) are the keys to doing just that. DMs select and hire new sales reps, guide product knowledge, develop selling skills, provide feedback, and take action to turn around or terminate poor performers. The average industry DM is responsible for generating tens of millions of dollars in sales through his or her teams. But, only 45 percent of industry DMs achieve their sales goals. Companies that succeed in raising the overall effectiveness of their DMs will create sustainable competitive advantage.